Citius Pharmaceuticals Inc
citiuspharma.comWhat Do They Do?
Develops and commercializes prescription medicines for cancer and critical-care patients, including LYMPHIR for lymphoma and candidates for catheter infections and hemorrhoids.
10-K for FY2025, filed Dec 23, 2025Citius Pharmaceuticals, Inc., headquartered in Cranford, New Jersey, is a biopharmaceutical company dedicated to the development and…View ↗
In December 2025, we became a commercial company with the launch of LYMPHIR by our majority owned subsidiary Citius Oncology. We also have…View ↗
Since its inception, the Company has devoted substantially all of its efforts to business planning, acquiring our proprietary technology…View ↗
How Do They Make Money?
No revenue reported yet.
10-K, filed Feb 6, 2014
Who Are Their Customers?
Cancer centers, community infusion centers and other institutions order LYMPHIR through wholesalers; the company targets hematologists, oncologists and dermatologist-oncologists to prescribe it.
10-K for FY2025, filed Dec 23, 2025 8-K, filed Aug 5, 2026LYMPHIR’s growing institutional footprint consists of leading academic and cancer treatment centers with recognized CTCL expertise.…View ↗
How Are They Changing?
-
Aug 21, 2026
Nasdaq extended the deadline to meet its minimum bid-price requirement
The shares continue to trade, but failure to comply by February 8, 2027 could lead to delisting.
Sources
8-K, filed Aug 21, 2026
On August 17, 2026, Citius Pharmaceuticals, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted…View ↗
-
Apr 29, 2026
Citius Oncology shipped its first LYMPHIR order to Europe
LYMPHIR was shipped through a regional partner for access through Named Patient Programs.
Sources
8-K, filed Apr 29, 2026
CRANFORD, N.J., April 29, 2026 – Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company…View ↗
LYMPHIR enters commercial sales
The older report describes I/ONTAK among the products in development; the latest report says Citius Oncology launched LYMPHIR and lists three other proprietary products still in development.
10-K for FY2022, filed Dec 22, 2022 10-K for FY2025, filed Dec 23, 2025Since its inception, the Company has devoted substantially all of its efforts to business planning, acquiring our proprietary technology…View ↗
Who Do They Compete With?
Competes with CorMedix, Great Lakes Pharmaceuticals, Cynata Therapeutics, Healios, and Mesoblast
10-K for FY2025, filed Dec 23, 2025At this time, there are no pharmacologic agents approved in the U.S. for the prevention or treatment of CRBSIs or CLABSIs in central venous…View ↗
Loading...
